Evogene
EVGN
18 hedge funds and large institutions have $6.18M invested in Evogene in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 17 → 18 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.43% less ownership
Funds ownership: 2.84% → 2.41% (-0.43%)
48% less capital invested
Capital invested by funds: $12M → $6.18M (-$5.81M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$151K |
| 2 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
+$70.1K |
| 3 |
SM
Senvest Management
New York
|
+$65.1K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$50.1K |
| 5 |
CCA
Clearwater Capital Advisors
Hoffman Estates,
Illinois
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.13M |
| 2 |
MCM
Moon Capital Management
New York
|
-$331K |
| 3 |
JP Morgan Chase
New York
|
-$125K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$12K |
| 5 |
Jane Street
New York
|
-$11.3K |
EVGN Hedge Fund Activity: Q2 2020 in Review
18 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2020, worth a combined $6.18M — down 48% from $12M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EVGN positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $151K. The largest seller was UBS Group, cutting an estimated $1.13M.
- 18 institutional investors held Evogene (EVGN) as of Q2 2020, up from 17 in Q1 2020.
- Funds reported $6.18M of Evogene stock for Q2 2020, down 48% quarter-over-quarter.
- 4 funds opened new Evogene positions in Q2 2020 and 3 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q2 2020 was ARK Investment Management, an estimated $151K added.
- The largest Evogene seller in Q2 2020 was UBS Group, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2020.